Is Fish Oil a Blood Thinner? Effects on Clotting

Fish oil is not a blood thinner in the medical sense of the term, but it does have a mild effect on how platelets clump together. Prescription blood thinners like warfarin and heparin work by directly interfering with the clotting cascade, and antiplatelet drugs like aspirin block a specific enzyme in platelets. Fish oil does something subtler: it shifts the balance of chemical signals that tell platelets whether to aggregate or not. That distinction matters, because the biochemical effect on platelets has consistently failed to translate into meaningful bleeding problems in clinical trials. The gap between what fish oil does in a test tube and what it does in your body is one of the more interesting puzzles in cardiovascular nutrition.

What Fish Oil Actually Does to Platelets

The omega-3 fatty acids in fish oil, primarily EPA and DHA, compete with arachidonic acid for the same enzymes in your platelets. Arachidonic acid normally gets converted into thromboxane A2, a molecule that strongly promotes platelet clumping. When EPA is present, the same enzyme converts it instead into thromboxane A3, which has much weaker pro-clumping activity. A similar swap happens in blood vessel walls, where EPA gets turned into a form of prostacyclin that discourages aggregation rather than encouraging it.¹ EPA also appears to dampen the production of other inflammatory mediators derived from arachidonic acid and may lower factor VII, one of the proteins involved in the clotting cascade.²

So on a molecular level, fish oil genuinely nudges platelet behavior in a less sticky direction. Measured in a lab, platelet aggregation does decrease in healthy people taking fish oil supplements.³ This is part of why fish oil developed its reputation as a blood thinner in the first place, and why some doctors historically told patients to stop taking it before surgery. The trouble is that a measurable change in platelet function on a lab test is not the same thing as a clinically relevant increase in bleeding. And the clinical data has been remarkably clear on this point.

Does Fish Oil Increase Bleeding Risk in Practice?

A large systematic review and meta-analysis published in the Journal of the American Heart Association pooled data from randomized trials comparing omega-3 fatty acids against placebo or no treatment. The rate of any bleeding event was essentially the same in both groups: roughly 2.6% with omega-3s versus 2.4% without. The difference was not statistically significant, and there was no increase in hemorrhagic stroke, intracranial bleeding, or gastrointestinal bleeding. No fatal bleeding events were reported in any of the included studies.⁴

An earlier systematic review in the Danish Medical Journal reached the same conclusion from a different angle: although fish oil supplements did reduce platelet aggregation in lab tests on healthy volunteers, that biochemical effect did not show up as increased bleeding or blood transfusions in surgical patients.³ The authors explicitly stated that their findings did not support discontinuing fish oil before surgery or other invasive procedures.

This disconnect between lab measurements and real-world outcomes is worth understanding. Platelet aggregation tests measure one narrow pathway, but your body has multiple overlapping systems that maintain clot formation. A modest reduction in one platelet signal can be compensated for by others. It would be like dimming one light in a stadium: measurable with an instrument, invisible to anyone watching the game.

Taking Fish Oil with Warfarin or Other Blood Thinners

If you’re already on a prescription anticoagulant, adding fish oil sounds like it could amplify the blood-thinning effect. Several studies have looked at this directly, and the answer has been consistently reassuring. A controlled trial of patients on chronic warfarin therapy found that adding fish oil at doses of 3 to 6 grams per day did not produce any statistically significant change in INR, the standard measure of how effectively warfarin is thinning the blood.⁵

A retrospective study of patients with atrial fibrillation and deep vein thrombosis told the same story: fish and krill oils did not alter the time spent in therapeutic range for warfarin, and there was no increase in bleeding incidents, even when the data was broken down by gender.⁶ That said, isolated case reports of INR changes in individual patients do exist in the medical literature, which is part of why package inserts and pharmacists still mention the theoretical interaction. The controlled studies, however, have consistently failed to confirm that it’s a meaningful clinical problem at typical supplement doses.

The story is similar for antiplatelet drugs. A study of patients taking both aspirin and clopidogrel, a common combination after stent placement, found that adding high-dose fish oil did not increase either major or minor bleeding episodes over a mean follow-up of about 33 months. If anything, minor bleeding was numerically lower in the fish oil group, though the difference wasn’t significant.⁷

Why Surgeons Used to Say “Stop Fish Oil”

For years, many surgeons and anesthesiologists told patients to stop fish oil supplements a week or two before elective surgery, treating them essentially the same as aspirin. That advice was based on the known antiplatelet mechanism and on general caution rather than on clinical evidence showing increased surgical bleeding. The evidence has since caught up, and it points in the opposite direction.

A study published in Circulation: Cardiovascular Quality and Outcomes looked specifically at fish oil and perioperative bleeding in cardiac surgery patients. Fish oil supplementation did not increase bleeding. In fact, patients who took it needed fewer blood transfusions, and higher levels of omega-3 fatty acids in the blood were actually associated with lower bleeding risk.⁸ A narrative review covering cardiac surgery patients more broadly confirmed these findings and called for a reconsideration of the blanket advice to stop fish oil before procedures.⁹

Professional guidelines have started to reflect this shift. The Society for Perioperative Assessment and Quality Improvement issued guidelines stating that fish oil and omega-3 preparations should be continued through surgery, noting that prior concerns about bleeding risk have not been confirmed by prospective studies.¹⁰ Not every surgical team has adopted this position yet, so you may still encounter the older advice. If your surgeon asks you to stop, it’s worth a conversation about the current evidence, but ultimately follow their guidance for your specific procedure.

The Exception for High-Dose Purified EPA

There is one scenario where the bleeding signal gets stronger, and it involves prescription-strength purified EPA, sold as icosapent ethyl (brand name Vascepa). This is not a standard fish oil supplement. It delivers 4 grams of pure EPA per day, much more than a typical capsule that contains a mix of EPA and DHA at lower total doses.

When the meta-analysis in the Journal of the American Heart Association restricted its analysis to trials using icosapent ethyl specifically, purified high-dose EPA was associated with about a 50% higher relative risk of any bleeding event compared with placebo. That sounds alarming, but the absolute numbers tell a more measured story: the actual increase was about 0.6 percentage points, meaning you would need to treat 166 people with icosapent ethyl for one additional person to experience any bleeding event. There was no significant increase in hemorrhagic stroke or intracranial bleeding even in this high-dose subgroup.⁴

This distinction matters for two reasons. First, if you’re taking standard over-the-counter fish oil at one or two grams a day, the high-dose EPA data doesn’t apply to you. Second, even at prescription strength, the absolute risk increase is small enough that the cardiovascular benefits of icosapent ethyl, which are substantial in the trial population it was designed for, generally outweigh the modest bleeding signal. Your cardiologist has likely already weighed this tradeoff if they prescribed it.

The Aspirin Combination Worth Knowing About

One nuance that sometimes gets lost in the “fish oil is safe” message involves the combination of fish oil and low-dose aspirin. A controlled study measured platelet function using a specialized analyzer and found that while EPA/DHA alone did not significantly reduce platelet function, and low-dose aspirin alone did not either in acute testing, the two taken together did produce a measurable drop in platelet function.¹¹ This is a lab finding, and as discussed earlier, lab changes in platelet function have not reliably translated into clinical bleeding. But it’s a reminder that combining multiple agents that each tilt platelet behavior, even mildly, can have additive effects.

For most healthy adults taking a daily baby aspirin and a fish oil capsule, this is probably not meaningful. But for someone who is also on a prescription antiplatelet drug, or who has an underlying bleeding disorder, the additive effect is worth mentioning to your doctor. The clinical trials that have looked at triple combinations of fish oil, aspirin, and clopidogrel haven’t found excess bleeding, as noted above, but those were conducted in monitored patients without pre-existing bleeding conditions.

Fish Oil and Postpartum Bleeding

Pregnancy is one area where the bleeding question gets more complicated. A hospital-based register study in Scandinavia found that women taking omega-3 supplements had about 25% higher odds of postpartum hemorrhage compared with non-users. The association was stronger for massive hemorrhage, where the odds were more than doubled, though the total number of massive bleeding events was small.¹² Women who stopped their omega-3 supplements by week 36 did not show the same association.

A prospective birth cohort study found a consistent signal: regular daily use of polyunsaturated fatty acid supplements was associated with greater blood loss during vaginal deliveries, although the increase was described as modest. A trend toward increased postpartum hemorrhage was observed among users, while no similar association appeared for cesarean deliveries.¹³

On the other hand, a randomized controlled trial that gave omega-3 supplements to prevent recurrent preterm birth found no difference in postpartum hemorrhage rates between the omega-3 group and placebo, with rates of about 14% and 12.5% respectively.¹⁴ The evidence here is mixed rather than settled. The observational studies suggest a possible increase in bleeding around delivery, particularly with continued use into the final weeks of pregnancy, while the randomized trial did not confirm it. Given this uncertainty, some obstetric providers now recommend stopping omega-3 supplements around week 36 as a precaution. If you’re pregnant and taking fish oil, this is a reasonable conversation to have with your midwife or obstetrician.

Children on Intravenous Fish Oil

A small but important population receiving fish oil in a very different form is pediatric patients who get omega-3 lipid emulsions intravenously, typically children with intestinal failure who can’t absorb fat from food. A review of 732 procedures in children receiving IV fish oil found that clinically significant post-procedural bleeding occurred in fewer than 1% of cases. IV fish oil therapy was not interrupted for any of the bleeding events, and no deaths from bleeding occurred.¹⁵

There is a caveat, though. A study using thromboelastography in neonatal piglets receiving sole omega-3 lipid emulsion (meaning no other fat source) identified abnormalities in clotting parameters, specifically in reaction time and the arachidonic acid pathway. The researchers cautioned that the potential for bleeding in high-risk infants with liver disease, a population where clotting is already compromised, should not be dismissed.¹⁶ This is a narrow and specialized concern that doesn’t apply to oral fish oil supplements in healthy children, but it illustrates that route, dose, and underlying health status all influence whether the antiplatelet properties of omega-3s become clinically relevant.

Where the Inuit Story Fits In

The modern interest in fish oil and clotting traces back to epidemiological observations from the late 1970s, when researchers noticed that Greenland Inuit populations had substantially lower rates of heart attack compared with Western populations, despite eating a very high-fat diet rich in marine omega-3s.¹⁷ The Inuit were also observed to have prolonged bleeding times, and this was initially interpreted as evidence that omega-3 fatty acids acted as natural blood thinners. Those early observations launched thousands of studies, and the picture that emerged over the following decades was more complicated than the original narrative suggested.

The Inuit’s prolonged bleeding times turned out to be a poor predictor of actual clinical bleeding, much like the platelet aggregation findings in modern supplement studies. The cardiovascular benefits of omega-3 intake proved real in some contexts but were eventually understood to involve anti-inflammatory and triglyceride-lowering effects at least as much as antiplatelet ones. Meanwhile, the idea that fish oil “thins your blood” became embedded in popular health advice, persisting long after the clinical evidence showed the effect to be trivial for most people. It’s a useful reminder that early observations in a specific population can generate a narrative that takes on a life of its own, even when later, more rigorous evidence tells a different story.